Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2013

01-10-2013 | Erratum

Erratum to: DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype

Authors: Eigil Kjeldsen, Christopher Veigaard

Published in: Cellular Oncology | Issue 5/2013

Login to get access

Excerpt

Erratum to: Cell Oncol. …
Metadata
Title
Erratum to: DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype
Authors
Eigil Kjeldsen
Christopher Veigaard
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0152-6

Other articles of this Issue 5/2013

Cellular Oncology 5/2013 Go to the issue

Original Paper

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients

Original Paper

Suppression of growth and migration by blocking the hedgehog signaling pathway in gastric cancer cells

Original Paper

FOXP3 expression and nodal metastasis of breast cancer

Original Paper

Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study

Original Paper

Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer

Original Paper

DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits